|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's Range||105.36 - 107.03|
|52 Week Range||93.39 - 113.46|
|PE Ratio (TTM)||N/A|
|Expense Ratio (net)||0.05%|
Vanguard, one of the fund issuers widely credited with spurring the low-cost, passive investing revolution, stepped into actively managed exchange traded funds Thursday by launching six factor-based ETFs. ...
In 4Q17, Abbott Laboratories (ABT) reported $828 million in net losses, which came in at $0.48 per share. The loss was due to the impact of a $1.46-billion charge due to the recent US tax reforms. Its adjusted tax rate in fiscal 4Q17 came in at 16.5%. In fiscal 2018, Abbott Laboratories expects an adjusted tax rate in the range of 14.5%–15%, primarily due to the impact of tax reform as well as global income mix.
The Zacks Analyst Blog Highlights: Select Sector SPDR Technology, Vanguard Small-Cap Growth, iShares MSCI ACWI, EventShares U.S. Tax Reform and Vanguard Value
2017 was another record year for assets flowing into exchange-traded funds (ETFs), and Vanguard was a big reason why. When it came to lost assets, not one Vanguard ETF was among last year’s worst offenders. By some estimates, Vanguard could be managing $10 trillion in total assets by 2023.
Although value has been out-of-favor relative to growth in recent years, more cautious advisors are increasingly looking towards value. We turn to our MoneyShow.com contributors for some top ETF ideas ...
In 3Q17, Merck’s (MRK) Keytruda generated revenue of ~$1.0 billion, compared with $346 million in 3Q16. In 3Q17, Keytruda witnessed ~19% growth QoQ (quarter-over-quarter). Sales volume growth in the US ...